Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceutica
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
09:01am, Wednesday, 03'rd Apr 2024
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
01:00pm, Monday, 01'st Apr 2024
ARS Pharmaceuticals, Inc. (SPRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
08:55am, Sunday, 31'st Mar 2024
Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks.
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
09:51am, Tuesday, 26'th Mar 2024
ARS Pharmaceuticals, Inc. (SPRY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation
LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceutic
NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation
Investors who lost money on ARS Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - SPRY
04:00am, Friday, 22'nd Mar 2024
NEW YORK, NY / ACCESSWIRE / March 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
06:00am, Friday, 15'th Mar 2024
Finding undervalued stocks is one of the key elements to making successful investments. Undervalued stocks are those that trade below their intrinsic value, meaning that the market has not fully re
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
09:01am, Monday, 05'th Feb 2024
SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients fr
ARS Pharmaceuticals: Surprise FDA Rejection Presents Cautious Opportunity
05:14pm, Friday, 08'th Dec 2023
ARS Pharmaceuticals, Inc. received a surprise Complete Response Letter from the FDA for its epinephrine nasal spray, neffy. The FDA's concern was that ARS Pharma did not conduct efficacy trials for ne
Penny Stocks To Buy? 3 That Insiders Are Investing $100,000+ In Now
11:51am, Wednesday, 04'th Oct 2023
When constructing a watch list of penny stocks, it is wise to closely monitor any legal insider trading activity. Though the rules surrounding insider trades are complex, legal filings by company exec
ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both
07:18pm, Friday, 22'nd Sep 2023
Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture significant market share from current standard (auto-i
Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday
12:42pm, Wednesday, 20'th Sep 2023
ARS Pharmaceutical is seeking the approval of Neffy, a nasal spray version of epinephrine. The FDA is seeking additional dosing studies before approving Neffy.
